Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
20. November 2020 09:10 ET
|
Auris Medical AG
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo
13. Oktober 2020 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Provides Business Update and Reports First Half 2020 Financial Results
17. September 2020 08:00 ET
|
Auris Medical AG
Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim dataPositive outcome from AM-201 trial in prevention of antipsychotic-induced weight gainAddition of new intranasal...
Auris Medical to Report First Half 2020 Financial Results and Provide Business Update on Thursday, September 17, 2020
11. September 2020 08:00 ET
|
Auris Medical AG
Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens
08. September 2020 08:30 ET
|
Auris Medical AG
Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99%Creation of dedicated...
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
03. September 2020 08:30 ET
|
Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...
Auris Medical Regains Listing Compliance with NASDAQ Minimum Bid Requirement
20. August 2020 16:30 ET
|
Auris Medical AG
Hamilton, Bermuda, August 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo
29. Juli 2020 08:30 ET
|
Auris Medical AG
Dose escalation completed as last patient enrolled into Part A of TRAVERS studyInterim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study
26. Mai 2020 08:30 ET
|
Auris Medical AG
Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gainTreatment well tolerated and safe with no adverse effectsEnrollment into Phase...
Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results
16. April 2020 07:00 ET
|
Auris Medical AG
Phase 1b trial with intranasal betahistine for prevention of antipsychotic-induced weight gain progressing towards final read-outPhase 2 trial with intranasal betahistine for treatment of acute...